For the year ending 2025-12-31, CBIO had $178,533K increase in cash & cash equivalents over the period. -$72,451K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| License revenue | 10,844 |
| Research and development expense-CR001 | 25,547 |
| Research and development expense-CR002 | 8,636 |
| Research and development expense-Discovery External Research And Development Costs | 1,952 |
| Personnel costs | 31,022 |
| Milestone and license fees | 84,710 |
| Professional and other fees | 11,609 |
| Other expense (income) | -690 |
| Provision for income taxes | 2,000 |
| Net loss | -153,942 |
| Share-based compensation expense | 13,300 |
| Research and development license expense | 80,000 |
| Depreciation expense | 84 |
| Non-cash interest expense | 2,185 |
| Non-cash research and development expense related to paragon option agreement | 0 |
| Non-cash lease expense | 212 |
| Accounts payable-Nonrelated Party | 2,081 |
| Accrued expenses and other current liabilities | 5,363 |
| Related party accounts payable and other current liabilities-Related Party | -7,081 |
| Deferred revenue | 4,156 |
| Deposit liability | 5,000 |
| Operating lease liability | -37 |
| Accounts receivable | 18,000 |
| Prepaid expenses and other current assets | 5,015 |
| Other assets | -162 |
| Net cash used in operating activities | -71,532 |
| Purchase of research and development license | 72,000 |
| Purchases of property and equipment | 919 |
| Net cash used in investing activities | -72,919 |
| Proceeds from the pre-closing financing, net | 143,007 |
| Proceeds from the private placement financing, net | 178,880 |
| Cash acquired in connection with the reverse recapitalization | 1,269 |
| Proceeds from early exercise of options | 5 |
| Proceeds from issuance of common stock | 0 |
| Proceeds from issuance of series seed convertible preferred stock | 0 |
| Proceeds from the issuance of notes payable, net of issuance costs | 0 |
| Payment of deferred offering costs | 0 |
| Repurchase of equity awards | -177 |
| Net cash provided by financing activities | 322,984 |
| Net increase in cash, cash equivalents, and restricted cash | 178,533 |
| Cash at beginning of period | 34,766 |
| Cash, cash equivalents, and restricted cash at end of period | 213,299 |
CRESCENT BIOPHARMA, INC. (CBIO)
CRESCENT BIOPHARMA, INC. (CBIO)